

WHAT IS CLAIMED IS:

SL 5
917

1. A test article comprising
a solid phase;
dry thromboplastin immobilized on or within the
solid phase, wherein the thromboplastin is substantially free
from substances which cause aberrant functioning intermediate
transition states as the thromboplastin is rehydrated with
liquid sample; and

10 coagulation neutral agents which facilitate
rehydration of the thromboplastin upon contact of the solid
phase with a liquid sample.

2. A test article as in claim 1, wherein the dry
thromboplastin is substantially free from aberrant functioning
thromboplastin transition states found in thromboplastin
purified from brain extract.

3. A test article as in claim 1, wherein the dry
thromboplastin is relipidated recombinant tissue factor.

4. A test article as in claim 1, wherein the
coagulation neutral agents are selected from the group
consisting of proteins, water soluble polymers, and
surfactants.

SL 5
927

5. A test strip comprising:
a permeable membrane having an application face and
an indicator face in lateral opposition, said membrane being
substantially free from an interference with a coagulation
pathway, and coagulation neutral agents intended to facilitate
liquid sample uptake and distribution into the test article;
dry thromboplastin impregnated within the membrane,
wherein the thromboplastin is substantially free from
substances which cause aberrant intermediate transition states
as the thromboplastin is rehydrated with liquid sample;

22

SL G7-5

a substrate impregnated within the membrane, which substrate produces a detectable signal upon activation by a component of the coagulation pathway;

whereby coagulation factor VII or VII(a) containing samples may be applied to the application face of the membrane, and a detectable signal produced on the indicator faced as a result of production of the coagulation pathway component.

6. The test strip as in claim 5, wherein the dry thromboplastin is substantially free from aberrant functioning thromboplastin transition states found in thromboplastin purified from brain extract.

7. The test strip as in claim 5, wherein the dry thromboplastin is relipidated recombinant tissue factor.

8. The test strip as in claim 5, wherein the coagulation neutral agents are selected from the group consisting of proteins, water soluble polymers, and surfactants.

SL G3

5

9. An improved prothrombin time assay of the type wherein a blood or plasma sample is applied to a solid phase to contact dry thromboplastin to initiate a detectable reaction, wherein the improvement comprises contacting a dry thromboplastin which is substantially free from substances which cause aberrant transition states as the thromboplastin is rehydrated with plasma sample.

10. An improved prothrombin time assay as in claim 9, wherein the dry thromboplastin is substantially free from aberrant functioning thromboplastin transition states found in thromboplastin purified from brain extract.

11. An improved prothrombin time assay as in claim 9, wherein the dry thromboplastin is relipidated recombinant tissue factor.

SL
cut

12. The method as in claim 9, wherein the coagulation neutral agents are selected from the group consisting of proteins, water soluble polymers, and surfactants.